apalutamide vs enzalutamide: insights on real-world survival benefits and clinical implications
Published 3 weeks ago • 247 plays • Length 6:38Download video MP4
Download video MP3
Similar videos
-
8:09
comparing apalutamide and enzalutamide in real-world treatment of mcspc
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment
-
34:48
apalutamide in metastatic castration-sensitive prostate cancer (mcspc): a case-based discussion
-
2:24
real-world psa responses to apalutamide or enzalutamide in mcspc
-
6:52
apalutamide: understanding its mechanism of action
-
11:49
lutetium-177 (pluvicto) vs. psma-actinium | #markscholzmd #alexscholz #pcri
-
55:35
immunotherapy for advanced prostate cancer with neal shore, md- ep 103
-
44:17
sglt-2 i, natriuresis & aquaresis: dapa shuttle-1 - dr. a. marton and prof. dr. j. titze (singapore)
-
3:28
apalutamide and the titan clinical trial
-
1:54
dr. plimack discusses trials investigating apalutamide, enzalutamide in m0 crpc
-
1:31
spartan vs. prosper: apalutamide or enzalutamide for nmcrpc?
-
6:40
updated overall survival outcomes in enzamet (anzup 1304)
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
8:33
titan phase 3 trial with apalutamide in metastatic castration sensitive prostate cancer
-
1:06
dr. bradley on adverse events associated with enzalutamide and apalutamide in prostate cancer
-
5:20
apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer.
-
1:28
apalutamide plus adt leads to survival benefit in mcspc
-
1:50
dr. kohli on the use of enzalutamide and apalutamide in mhspc
-
3:11
erleada or apalutamide adt treatment
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
3:11
real-world insights of arsis and adts in mcspc